{"id":"hidac-high-dose-cytarabine","safety":{"commonSideEffects":[{"rate":null,"effect":"Myelosuppression (neutropenia, thrombocytopenia, anemia)"},{"rate":null,"effect":"Neurotoxicity (cerebellar syndrome, encephalopathy)"},{"rate":null,"effect":"Mucositis"},{"rate":null,"effect":"Nausea and vomiting"},{"rate":null,"effect":"Hepatotoxicity"},{"rate":null,"effect":"Infection"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Cytarabine is a cytidine analog that is phosphorylated intracellularly and incorporated into DNA, causing chain termination and inhibition of DNA polymerase. At high doses, it achieves greater intracellular accumulation and DNA incorporation, resulting in enhanced cytotoxic effects against leukemic and lymphoma cells. The drug is particularly effective in hematologic malignancies due to the high proliferation rate of these cells.","oneSentence":"High-dose cytarabine is a nucleoside analog that inhibits DNA synthesis by being incorporated into DNA, leading to cell death in rapidly dividing cells.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:14:54.156Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Acute myeloid leukemia (AML)"},{"name":"Acute lymphoblastic leukemia (ALL)"},{"name":"Non-Hodgkin lymphoma"},{"name":"Hodgkin lymphoma"}]},"trialDetails":[{"nctId":"NCT06226571","phase":"PHASE1","title":"A Study of SNDX-5613 in Combination With Intensive Chemotherapy in Participants With Acute Myeloid Leukemias","status":"RECRUITING","sponsor":"Syndax Pharmaceuticals","startDate":"2024-05-21","conditions":"Acute Myeloid Leukemias","enrollment":76},{"nctId":"NCT07259707","phase":"PHASE2","title":"Gilteritinib Plus VA Followed By Consolidation Chemotherapy in Newly Diagnosed FLT3-ITD+ AML","status":"RECRUITING","sponsor":"First Affiliated Hospital of Zhejiang University","startDate":"2026-01-25","conditions":"Acute Myeloid Leukemia, FLT3 Internal Tandem Duplication Positive, Intermediate Risk Acute Myeloid Leukemia","enrollment":25},{"nctId":"NCT03900949","phase":"PHASE1","title":"Gentuzumab Ozogamicin and Midostaurin Combination With Standard Cytarabine and Danunorubi Midostaurin as a Novel Approach to Treating Patients With Newly Diagnosed FLT-3 Mutated Acute Myeloid Leukemia","status":"COMPLETED","sponsor":"Uma Borate","startDate":"2019-03-13","conditions":"Acute Myeloid Leukemia","enrollment":21},{"nctId":"NCT02756962","phase":"PHASE2","title":"Improving Risk Assessment of AML With a Precision Genomic Strategy to Assess Mutation Clearance","status":"ACTIVE_NOT_RECRUITING","sponsor":"Washington University School of Medicine","startDate":"2016-07-06","conditions":"Acute Myeloid Leukemia","enrollment":107},{"nctId":"NCT04914676","phase":"PHASE2","title":"Accelerated Dose Schedule of Cytarabine Consolidation Therapy for Older Patients With Acute Myeloid Leukemia (AML) in Complete Remission","status":"TERMINATED","sponsor":"University of Florida","startDate":"2022-03-08","conditions":"Acute Myeloid Leukemia","enrollment":5},{"nctId":"NCT02768792","phase":"PHASE2","title":"High Dose Cytarabine Followed by Pembrolizumab in Relapsed/Refractory AML","status":"COMPLETED","sponsor":"UNC Lineberger Comprehensive Cancer Center","startDate":"2016-08-22","conditions":"Acute Myeloid Leukemia, in Relapse","enrollment":38},{"nctId":"NCT02633137","phase":"PHASE2","title":"Sequential Chemotherapy and Lenalidomide Followed by Rituximab and Lenalidomide Maintenance for Untreated Mantle Cell Lymphoma","status":"COMPLETED","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2015-12-14","conditions":"Mantle Cell Lymphoma, Untreated","enrollment":49},{"nctId":"NCT02920008","phase":"PHASE3","title":"Phase 3 Randomized, Open-Label Study of Guadecitabine vs Treatment Choice in Previously Treated Acute Myeloid Leukemia","status":"COMPLETED","sponsor":"Astex Pharmaceuticals, Inc.","startDate":"2017-03-16","conditions":"Acute Myeloid Leukemia","enrollment":302},{"nctId":"NCT02013167","phase":"PHASE3","title":"Blinatumomab Versus Standard of Care Chemotherapy in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL)","status":"TERMINATED","sponsor":"Amgen","startDate":"2014-01-03","conditions":"Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia","enrollment":405},{"nctId":"NCT01484093","phase":"PHASE1, PHASE2","title":"Sequential Chemo-Radioimmunotherapy Followed by Autologous Transplantation for Patients With Untreated Advanced Stage Mantle Cell Lymphoma","status":"COMPLETED","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2011-11-29","conditions":"Mantle Cell Lymphoma","enrollment":96},{"nctId":"NCT02927938","phase":"PHASE3","title":"Leukemia Stem Cell Detection in Acute Myeloid Leukemia","status":"TERMINATED","sponsor":"Wake Forest University Health Sciences","startDate":"2016-09","conditions":"Acute Myeloid Leukemia (AML)","enrollment":18},{"nctId":"NCT01246752","phase":"PHASE3","title":"Haematopoietic Stem Cell Transplantation (HSCT) in Comparison to Conventional Consolidation Therapy for Patients With Acute Myeloid Leukemia (AML) (Intermediate Risk) </= 60y. After First CR","status":"TERMINATED","sponsor":"University Hospital Carl Gustav Carus","startDate":"2011-02-10","conditions":"Leukemia, Myeloid, Acute","enrollment":143},{"nctId":"NCT01830361","phase":"PHASE2","title":"Trial to Assess the Efficacy of Midostaurin (PKC412) in Patients With c-KIT or FLT3-ITD Mutated t(8;21) AML","status":"COMPLETED","sponsor":"Technische Universität Dresden","startDate":"2013-03-13","conditions":"Acute Myeloid Leukemia","enrollment":18},{"nctId":"NCT00632827","phase":"PHASE2","title":"Treatment of PTCL With Aggressive Induction Therapy Followed by Autologous SCT Using Denileukin Diftitox (Ontak)","status":"TERMINATED","sponsor":"University of California, San Francisco","startDate":"2008-07-01","conditions":"Peripheral T-Cell Lymphoma","enrollment":21},{"nctId":"NCT02573363","phase":"PHASE1","title":"Selinexor With Combination Chemotherapy in Treating Patients With Acute Myeloid Leukemia","status":"COMPLETED","sponsor":"University of Chicago","startDate":"2015-10-07","conditions":"Acute Myeloid Leukemia","enrollment":25},{"nctId":"NCT04100330","phase":"PHASE2","title":"A Study of Ficlatuzumab With HiDAC and HiDAC Alone in Adults With Relapsed or Refractory Acute Myeloid Leukemia","status":"WITHDRAWN","sponsor":"AVEO Pharmaceuticals, Inc.","startDate":"2020-01-31","conditions":"Acute Myeloid Leukemia","enrollment":""},{"nctId":"NCT02109627","phase":"PHASE1","title":"Ficlatuzumab With High Dose Cytarabine in Relapsed and Refractory AML","status":"TERMINATED","sponsor":"C. Babis Andreadis","startDate":"2015-05-01","conditions":"Acute Myeloid Leukemia, Relapsed Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia","enrollment":17},{"nctId":"NCT01564784","phase":"PHASE3","title":"A Study Of Inotuzumab Ozogamicin Versus Investigator's Choice Of Chemotherapy In Patients With Relapsed Or Refractory Acute Lymphoblastic Leukemia","status":"COMPLETED","sponsor":"Pfizer","startDate":"2012-08-02","conditions":"Acute Lymphoblastic Leukemia","enrollment":326},{"nctId":"NCT02101983","phase":"NA","title":"Pilot Study of Feasibility of Outpatient Daily High Dose Cytarabine as Consolidation Therapy for Older Patients With Acute Myeloid Leukemia (AML)","status":"COMPLETED","sponsor":"University of Rochester","startDate":"2011-05","conditions":"Acute Myeloid Leukemia","enrollment":11},{"nctId":"NCT00079482","phase":"PHASE2","title":"Study of CEP-701 (Lestaurtinib) in Patients With Acute Myeloid Leukemia (AML)","status":"COMPLETED","sponsor":"Cephalon","startDate":"2003-10","conditions":"Acute Myeloid Leukemia","enrollment":224},{"nctId":"NCT01297543","phase":"PHASE1, PHASE2","title":"Safety Study of Human Myeloid Progenitor Cells (CLT-008) After Chemotherapy for Leukemia","status":"COMPLETED","sponsor":"Cellerant Therapeutics","startDate":"2011-03","conditions":"Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Chronic Myeloid Leukemia","enrollment":45},{"nctId":"NCT00565058","phase":"PHASE2","title":"Combination of GTI-2040 and Cytarabine in the Treatment of Refractory and Relapsed Acute Myeloid Leukemia (AML)","status":"COMPLETED","sponsor":"Aptose Biosciences Inc.","startDate":"2007-08","conditions":"Acute Myeloid Leukemia","enrollment":27},{"nctId":"NCT01222143","phase":"PHASE1, PHASE2","title":"Safety and Efficacy Study of Nilotinib Combined With Mitoxantrone, Etoposide, and High-dose Cytarabine Induction Chemotherapy Followed by Consolidation for Patients With C-kit Positive Acute Myeloid Leukemia","status":"TERMINATED","sponsor":"University Health Network, Toronto","startDate":"2010-10","conditions":"Acute Myeloid Leukemia","enrollment":12},{"nctId":"NCT00774046","phase":"PHASE2","title":"High-dose Cytarabine/Mitoxantrone Followed by Autotransplantation for t-MDS/t-AML","status":"COMPLETED","sponsor":"University of Chicago","startDate":"2002-12","conditions":"Myelodysplastic Syndrome, Acute Myeloid Leukemia","enrollment":32},{"nctId":"NCT00006363","phase":"PHASE3","title":"Combination Chemotherapy With or Without PSC 833, Peripheral Stem Cell Transplantation, and/or Interleukin-2 in Treating Patients With Acute Myeloid Leukemia","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2000-11","conditions":"Adult Acute Basophilic Leukemia, Adult Acute Eosinophilic Leukemia, Adult Acute Erythroid Leukemia (M6)","enrollment":720},{"nctId":"NCT00017342","phase":"PHASE2","title":"Bryostatin 1 and Cytarabine in Treating Patients With Relapsed Acute Myelogenous Leukemia","status":"COMPLETED","sponsor":"Virginia Commonwealth University","startDate":"2001-07","conditions":"Leukemia","enrollment":""},{"nctId":"NCT00003079","phase":"PHASE1","title":"Bryostatin 1 and High Dose Cytarabine in Treating Patients With Refractory or Relapsed Leukemia or Lymphoma","status":"COMPLETED","sponsor":"Virginia Commonwealth University","startDate":"1997-09","conditions":"Leukemia, Lymphoma","enrollment":30}],"_emaApprovals":[],"_faersSignals":[{"count":2,"reaction":"FEBRILE NEUTROPENIA"},{"count":1,"reaction":"ACUTE HEPATIC FAILURE"},{"count":1,"reaction":"ANAEMIA"},{"count":1,"reaction":"ATELECTASIS"},{"count":1,"reaction":"BONE MARROW FAILURE"},{"count":1,"reaction":"PNEUMONIA"},{"count":1,"reaction":"THROMBOCYTOPENIA"}],"_approvalHistory":[],"publicationCount":90,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"HIDAC (high dose cytarabine)","genericName":"HIDAC (high dose cytarabine)","companyName":"Pfizer","companyId":"pfizer","modality":"Small molecule","firstApprovalDate":"","aiSummary":"High-dose cytarabine is a nucleoside analog that inhibits DNA synthesis by being incorporated into DNA, leading to cell death in rapidly dividing cells. Used for Acute myeloid leukemia (AML), Acute lymphoblastic leukemia (ALL), Non-Hodgkin lymphoma.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}